BICYCLE THERAPEUTICS ($BCYC) is expected to release its quarterly earnings data on Monday, August 4th before market open, per Finnhub. Analysts are expecting revenue of $8,887,821 and earnings of -$0.97 per share.
You can see Quiver Quantitative's $BCYC stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BICYCLE THERAPEUTICS Insider Trading Activity
BICYCLE THERAPEUTICS insiders have traded $BCYC stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $BCYC stock by insiders over the last 6 months:
- KEVIN LEE (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 4 sales selling 11,130 shares for an estimated $83,448.
- ALISTAIR MILNES (CHIEF OPERATING OFFICER) has made 0 purchases and 4 sales selling 4,286 shares for an estimated $32,184.
- MICHAEL SKYNNER (CHIEF TECHNOLOGY OFFICER) has made 0 purchases and 4 sales selling 3,643 shares for an estimated $27,328.
- MICHAEL CHARLES FERGUSON HANNAY (CHIEF PROD & SUPPLY CHAIN OFF) has made 0 purchases and 4 sales selling 1,455 shares for an estimated $10,940.
- TRAVIS ALVIN THOMPSON (CHIEF ACCOUNTING OFFICER) has made 0 purchases and 4 sales selling 625 shares for an estimated $4,704.
- ALETHIA YOUNG (Chief Financial Officer) has made 0 purchases and 2 sales selling 419 shares for an estimated $3,170.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BICYCLE THERAPEUTICS Hedge Fund Activity
We have seen 40 institutional investors add shares of BICYCLE THERAPEUTICS stock to their portfolio, and 46 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 862,831 shares (-18.9%) from their portfolio in Q1 2025, for an estimated $7,325,435
- LONG FOCUS CAPITAL MANAGEMENT, LLC added 750,661 shares (+138.2%) to their portfolio in Q1 2025, for an estimated $6,373,111
- DEEP TRACK CAPITAL, LP removed 509,065 shares (-39.9%) from their portfolio in Q1 2025, for an estimated $4,321,961
- ARMISTICE CAPITAL, LLC added 476,000 shares (+21.7%) to their portfolio in Q1 2025, for an estimated $4,041,240
- TYBOURNE CAPITAL MANAGEMENT (HK) LTD added 417,400 shares (+72.4%) to their portfolio in Q2 2025, for an estimated $2,900,930
- JEFFERIES FINANCIAL GROUP INC. added 408,889 shares (+inf%) to their portfolio in Q1 2025, for an estimated $3,471,467
- WOODLINE PARTNERS LP added 363,751 shares (+inf%) to their portfolio in Q1 2025, for an estimated $3,088,245
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BICYCLE THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $BCYC in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 07/17/2025
- JMP Securities issued a "Market Outperform" rating on 05/02/2025
- Needham issued a "Buy" rating on 05/02/2025
- Barclays issued a "Overweight" rating on 05/01/2025
- Citizens Capital Markets issued a "Market Outperform" rating on 02/26/2025
- HC Wainwright & Co. issued a "Buy" rating on 02/26/2025
To track analyst ratings and price targets for BICYCLE THERAPEUTICS, check out Quiver Quantitative's $BCYC forecast page.
BICYCLE THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $BCYC recently. We have seen 9 analysts offer price targets for $BCYC in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Leonid Timashev from RBC Capital set a target price of $25.0 on 07/17/2025
- Jeffrey Hung from Morgan Stanley set a target price of $17.0 on 05/06/2025
- Kalpit Patel from B. Riley Securities set a target price of $14.0 on 05/02/2025
- Reni Benjamin from JMP Securities set a target price of $22.0 on 05/02/2025
- Ami Fadia from Needham set a target price of $29.0 on 05/02/2025
- Peter Lawson from Barclays set a target price of $15.0 on 05/01/2025
- Reni Benjamin from Citizens Capital Markets set a target price of $26.0 on 02/26/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
